Drug Trial Radar · NCT04353466
Assessing the Impact of Elelyso on Bone Involvement Currently Treated With Other ERTs
Last checked: Nov 20, 2026Latest source record: Oct 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jan 1, 2017
Primary completion
Jul 31, 2021
Study completion Jul 31, 2021
Sponsor
- Lead sponsor
- Shaare Zedek Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Pfizer
- First posted
- Apr 20, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to assess Elelyso treatment on bone disease in Gaucher patients currently treated with other enzyme replacement therapy. Experience from early access program (2009-2012) has suggested that some patients who have been stable on imiglucerase have shown poor scores of QCSI with Fat Fraction below the cut off point of 0.23 which is considered "bone at risk", and have demonstrated remarkable improvement upon switching to Elelyso, including particularly 2 patients who did not have any change in dose or any drug interruption prior to the switch. These findings may be explained by the better glycan structure of imiglucerase (see Tekoah et al, 2013). The fact that in many patients prevention of bony complications is the main indication for ERT highlights the importance of this study, as all clinical trials of all ERTS heretofore did not include the bones as primary or secondary end-points but only as exploratory, and as such had only limited value,
Conditions
- Gaucher Disease, Type 1
Interventions
quantitative chemical shift imaging (QCSI)Procedure
Poor scores of QCSI with Fat Fraction below the cut off point of 0.3 which is considered "bone at risk"
ElelysoDrug
intravenous (IV) infusions of Elelyso
Primary outcomes
What the sponsor says the trial is designed to measure.
- QCSI results at 12 months, Fat fraction under 0.3.Time frame: 12 months
- QCSI results at 24 months, Fat fraction under 0.3.Time frame: 24 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.